{"nctId":"NCT00308308","briefTitle":"Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes","startDateStruct":{"date":"2006-02"},"conditions":["Diabetes, Type I"],"count":589,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Technosphere Insulin"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Active comparator"]}],"interventions":[{"name":"Technosphere Insulin","otherNames":[]},{"name":"Active comparator","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of type 1 diabetes for at least 1 year\n* Nonsmokers for prior 6 months\n* BMI less than or equal to 35kg/m2\n* HbA1c \\> or = 7% and \\< or = 11%\n* Serum creatinine \\< or = 1.8 mg/dL in female subjects and \\< or = 2.0 mg/dL in male subjects\n* FEV1 \\> or = 70% of predicted, DLco \\> or = 70% , TLC \\> or = 80% predicted\n* Maintenance of a treatment regimen of insulin less than or equal to 1.4 iu/kg/day\n* Urine cotinine \\< or = 100 ng/mL\n\nExclusion Criteria:\n\n* History of chronic obstructive pulmonary disease, asthma, any other clinically significant pulmonary disease confirmed by documented history, pulmonary function testing or radiologic findings\n* Evidence of severe complications of diabetes\n* Aminotransferase and/or alanine aminotransferase \\> than 3 times the upper limit of normal","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Compare the Mean Change From Baseline to Week 52 in HbA1c","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.058"},{"groupId":"OG001","value":"-0.37","spread":"0.059"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Weight to Week 52","description":"Change from baseline in weight at Week 52","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.32"},{"groupId":"OG001","value":"1.4","spread":"0.30"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose to Week 52","description":"Change from baseline in fasting plasma glucose at Week 52","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.5","spread":"5.61"},{"groupId":"OG001","value":"-25.7","spread":"5.23"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%","description":"Number of subjects achieving week 52 HbA1c levels less than or equal to 7.0%","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Total Hypoglycemia","description":"Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement \\<= 63 mg/dL, regardless of symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.67","spread":null},{"groupId":"OG001","value":"92.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Severe Hypoglycemia","description":"Severe hypoglycemia occurs when all 3 of the following occur simultaneously:\n\n* Subject requires the assistance of another person;\n* Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness);\n* Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR,\n* Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.08","spread":null},{"groupId":"OG001","value":"36.40","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Hypoglycemia Event Rate","description":"Number of Hypoglycemic Events/Total Subject Exposure Time (in months)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":null},{"groupId":"OG001","value":"1.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Severe Hypoglycemia Event Rate","description":"Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":52,"n":293},"commonTop":["Hypoglycaemia","Cough","Upper respiratory tract infection","Nasopharyngitis","Influenza"]}}}